Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial

Langton Hewer S, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Williamson PR, TORPEDO-CF Study Group
Record ID 32010000408
English
Authors' objectives: Children and adults with cystic fibrosis are prone to chest infections and these infections can cause long term damage to the lungs, which can affect the health and long term survival of the patient. There are a number of different organisms that cause these infections, one of the most important of which is known as Pseudomonas aeruginosa (there is no lay term for this organism). Pseudomonas is treated with oral (by mouth), intravenous (directly into the blood) and nebulised antibiotics (inhaled as an aerosol), usually in combination. Sometimes doctors choose to treat the patient in the community with three months of oral and at least three months of nebulised antibiotics and sometimes choose to admit the patient to hospital and treat for 10-14 days with intravenous treatment as well as continuing the same nebulised treatment for three months. Despite there being substantial differences to the patient and family in terms of what these two treatment choices offer, at present it is not possible for medical teams to say if intravenous treatment is better than oral treatment in terms of their ability to totally clear the infection from the body. This study addresses this question and will also address the question of cost of each form of treatment. Cost will be measured in terms of direct costs of the treatment including cost of medication and of giving the medication (including the cost of hospital admission where appropriate) and in terms of indirect costs such as time missed from school and work and the relative amount of inconvenience experienced by the patient and family for each form of treatment.
Details
Project Status: Completed
Year Published: 2020
Requestor: NIHR Health Technology Assessment programme
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England
Pubmed ID: 33007285
MeSH Terms
  • Pseudomonas aeruginosa
  • Pseudomonas Infections
  • Cystic Fibrosis
  • Anti-Bacterial Agents
  • Adult
  • Child
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.